EMA Executive Director Guido Rasi Takes Office
The new executive director of the European Medicines Agency begins appointment.
Professor Guido Rasi has begun his five-year appointment as executive director of the European Medicines Agency (EMA). Rasi was nominated for the position on Oct. 1, 2015 and was appointed Oct. 13, 2015. Rasi served previously as executive director of EMA from November 2011–November 2014.
“I am very happy to be back at the helm of the Agency,” Rasi said in a press release. “We are currently undergoing the most significant transformation of the system of medicine development and authorization that I have seen during my 35-year career in public health, either as a doctor, a researcher or a regulator. It is exciting and challenging to be leading the Agency during this time.”
Professor Rasi previously served as EMA’s principal adviser in charge of strategy and was the director-general of the Italian Medicines Agency from 2008 to
2011. He also worked at the Institute for Experimental Medicine of the National Research Council, Italy and was the director of the Institute of Molecular Medicine of the National Research Council in Rome. Professor Rasi holds a degree in medicine and surgery, with specializations in internal medicine, allergology, and clinical immunology from the University of Rome.
Source: EMA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
